Niet-alcoholische leververvetting (NAFLD) is een veelvoorkomende leveraandoening in Westerse landen. Deze aandoening omvat goedaardige leververvetting (benigne steatose) bekend onder de noemer ‘non-alcoholic fatty liver’ (NAFL) en niet-alcoholische steatohepatitis, ‘non-alcoholic steatohepatitis’ (NASH). Bij 15 tot 30% van de NAFLD-patiënten ontstaat NASH, wat te beschouwen is als de levervariant van het metabool syndroom (Koek, 2011 NTVG).
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Verschenen in
Referenties
Targher G, Leonardo A, Rossini M. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? J Endocrinol Invest. 2015;38:817-825.
Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is
associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389-397.
Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of followup. Hepatology. 2015;61:1547-1554.
Obesity and overweight. WHO factsheet 2018. https://www.hepatitisinfo.nl/kennisbank/aDU1387_Leververvetting-NAFLD-en...
Stephen A Harrison et al, NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet (2018). DOI: 10.1016/S0140-6736(18)30474-4
https://medicalxpress.com/news/2018-03-gastrointestinal-hormone-symptoms...
Van Daele, 2018, UZ_Magazine https://www.uzleuven.be/sites/default/files/Centraal/Over_ons/Publicatie...
Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B,Subbarayan S, Webb A, Hecht J, Cusi K. High Prevalence of Nonalcoholic FattyLiver Disease in Patients With Type 2 Diabetes Mellitus and Normal PlasmaAminotransferase Levels. J Clin Endocrinol Metab. 2015 Jun;100(6):2231-8. doi:10.1210/jc.2015-1966. Epub 2015 Apr 17. PubMed PMID: 25885947.
Henkel J, Alfine E, Saín J, Jöhrens K, Weber D, Castro JP, König J, Stuhlmann C, Vahrenbrink M, Jonas W, Kleinridders A, Püschel GP. Soybean Oil-DerivedPoly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by DietaryCholesterol. Nutrients. 2018 Sep 18;10(9). pii: E1326. doi: 10.3390/nu10091326. PubMed PMID: 30231595.
Musso G, Cassader M, Olivetti C, et al. Association of obstructive sleep apnoea with the
presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14:417-431.
Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath. 2018; Jan 15. doi: 10.1007/s11325-018-1625-
Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
Spencer MD, Hamp TJ, Reid RW,Fischer LM, Zeisel SH, Fodor AA.Association between composition of thehuman gastrointestinal microbiome anddevelopment of fatty liver with choline deficiency. Gastroenterology 2011; 140:976–86.
Zhu L, Baker SS, Gill C, et al.Characterization of gut microbiomes innonalcoholic steatohepatitis (NASH)patients: a connection betweenendogenous alcohol and NASH.Hepatology 2013; 57: 601–9.
Mouzaki M, Comelli E, Arendt B, et al.Intestinal microbiota in patients withnon-alcoholic fatty liver disease.Hepatology 2013; 58: 120–7.
Zeisel SH. Choline: needed for normal development of memory. J Am Coll Nutr 2000;19:528S-31S
Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasmatransforming growth factor-beta1 level and efficacy of alpha-tocopherolin patients with non-alcoholic steatohepatitis: a pilot study. AlimentPharmacol Ther. 2001;15:1667-72.
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E andvitamin C treatment improves fibrosis in patients with nonalcoholicsteatohepatitis. Am J Gastroenterol. 2003;98:2485-90.
Jansen PLM. Niet-alcoholische steatohepatitis: diagnostiek, pathogenese,behandeling en prognose. Ned Tijdschr Geneeskd. 2005;149:289-94.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004;24:3-20.
Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37:154-60.
